Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 6/20 | 0.35 |
| ▸ | PIEZO1 | Q92508 | 1/20 | 0.35 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29791140 | 0.69 | CYP2A6 (0.50) | HDAC1HDAC8HDAC6HTTRECQL | |
| SCHEMBL902694 | 0.69 | CYP2A6 (0.50) | HDAC1HDAC8HDAC6HTTRECQL | |
| SCHEMBL29454745 | 0.68 | NISCH (0.50) | HTTRECQLCYP1A2ALDH1A1KDM4E | |
| SCHEMBL78566 | 0.68 | NISCH (0.50) | HTTRECQLCYP1A2ALDH1A1KDM4E | |
| SCHEMBL29598957 | 0.68 | NISCH (0.50) | HTTRECQLCYP1A2ALDH1A1KDM4E | |
| SCHEMBL1027238 | 0.68 | CYP2A6 (0.48) | HDAC1HDAC8HDAC6HTTRECQL | |
| SCHEMBL355117 | 0.68 | CYP2A6 (0.53) | HTTCYP1A2ALDH1A1KDM4EHPGD | |
| SCHEMBL2900102 | 0.67 | CYP19A1 (0.36) | — | |
| SCHEMBL18049512 | 0.67 | HTT (0.47) | HDAC1HDAC8HDAC6HTTRECQL | |
| SCHEMBL2405897 | 0.67 | IDO1 (0.33) | HDAC1HDAC6CYP1A2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1212299-B1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LTD (GB) | 2009-04-08 | — | — | EP | claimed |
| EP-1487827-A1 | ANTI-INFLAMMATORY MORPHOLIN-ACETAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | claimed |
| WO-2003082862-A1 | ANTI-INFLAMMATORY MORPHOLIN-ACETAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | claimed |
| EP-4101297-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Pharmaceuticals, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| CN-114939117-A | Method of treating vascular leak syndrome | 视点制药公司 | 2022-08-26 | — | — | CN | disclosed |
| US-20220117946-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2022-04-21 | — | — | US | disclosed |
| US-20220016086-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | EyePoint Pharmaceuticals, Inc. | 2022-01-20 | — | — | US | disclosed |
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2020-11-19 | — | — | US | disclosed |
| EP-3323815-B1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS LLC (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20200277267-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2020-09-03 | — | — | US | disclosed |
| US-20200253936-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2020-08-13 | — | — | US | disclosed |
| EP-2041102-A2 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | The Procter & Gamble Company (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2009018844-A1 | THIAZOLE-PIPERIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | ORIDIS BIOMED FORSCHUNGS- UND ENTWICKLUNGS GMBH (AT) | 2009-02-12 | — | — | WO | disclosed |
| US-20080108631-A1 | 4-{2-[2-(tert-Butoxycarbonyl)-3-phenylpropanamido]-2-(4-ethylthiazol-2-yl)ethyl}phenylsulfamic acid; anticarcinogenic, antitumor, antidiabrtic agent; angiogenesis inhibitor; sarcoid, syphilis, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis | THE PROCTER & GAMBLE COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| WO-2008002569-A2 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
| EP-1832585-A1 | Thiazole-piperidine derivatives for treatment of hyperproliferative diseases | ORIDIS BIOMED Forschungs- und Entwicklungs GmbH (AT) | 2007-09-12 | — | — | EP | disclosed |
| US-20060211636-A1 | Macrolide Antibiotics | ALIHODZIC SULEJMAN | 2006-09-21 | — | — | US | disclosed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | disclosed |
| EP-1487827-A1 | ANTI-INFLAMMATORY MORPHOLIN-ACETAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003082862-A1 | ANTI-INFLAMMATORY MORPHOLIN-ACETAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220117946-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | HDAC1 2399/4885HDAC8 1978/4885HDAC6 2317/4885 |
| US-20050215495-A1 | Macrolide antibiotics | IL1R1, MRPL12, RPS21 | HDAC1 226/4885HDAC8 1329/4885HDAC6 140/4885 |
| US-20200253936-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | HDAC1 2399/4885HDAC8 1978/4885HDAC6 2317/4885 |
| US-20220016086-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | FLT4, VEGFA, AQP3 | HDAC1 2269/4885HDAC8 2726/4885HDAC6 2112/4885 |
| US-20060211636-A1 | Macrolide Antibiotics | IL1R1, MRPL12, RPS21 | HDAC1 226/4885HDAC8 1329/4885HDAC6 140/4885 |
| US-20200277267-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | HDAC1 1627/4885HDAC8 1115/4885HDAC6 2814/4885 |
| US-20080108631-A1 | 4-{2-[2-(tert-Butoxycarbonyl)-3-phenylpropanamido]-2-(4-ethylthiazol-2-yl)ethyl}phenylsulfamic acid; anticarcinogenic, antitumor, antidiabrtic agent; angiogenesis inhibitor; sarcoid, syphilis, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis | VASP, DUSP15, PPP5C | HDAC1 2567/4885HDAC8 2824/4885HDAC6 1850/4885 |
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | HDAC1 3177/4885HDAC8 1960/4885HDAC6 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.